Objective
Statins are a class of drugs used to lower cholesterol in patients who are at a high risk of cardiovascular disease. Statins could potentially reduce the risk of diabetic polyneuropathy by exerting lipid-lowering and anti-inflammatory effects. Alternatively, however, statins have also been associated with neurotoxicity and could potentially damage nerves. To shed light on the debate, researchers examined whether statin therapy affects the risk of diabetic polyneuropathy.
Conclusion
Statin therapy is unlikely to increase or mitigate diabetic polyneuropathy risk in patients with type 2 diabetes. However, there may be a small risk of diabetic polyneuropathy to new users, which vanishes after 2 or more years of follow-up.